Princess Margaret Cancer Center
Toronto, Ontario, Canada
23 recruiting
Showing 1–20 of 36 trials
Recruiting
Phase 3
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Lymphoma
Hoffmann-La Roche182 enrolled76 locationsNCT06084936
Recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
Myeloproliferative Neoplasms
Incyte Corporation186 enrolled30 locationsNCT06313593
Recruiting
Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Solid Tumors
Incyte Corporation710 enrolled37 locationsNCT06179160
Recruiting
Phase 3
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Chronic Graft Versus Host Disease
Incyte Corporation240 enrolled119 locationsNCT06585774
Recruiting
Phase 1Phase 2
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Myelofibrosis
Sumitomo Pharma America, Inc.240 enrolled84 locationsNCT04176198
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
CRC (Colorectal Cancer)
Incyte Corporation700 enrolled273 locationsNCT07284849
Recruiting
Phase 3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Leukemia
Daiichi Sankyo700 enrolled288 locationsNCT06578247
Recruiting
Not Applicable
Virtual Vs Telephone Education in Radiotherapy
RadiotherapyPatient Education
University Health Network, Toronto130 enrolled1 locationNCT07255196
Recruiting
Phase 1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Metastatic Colorectal Cancer
Hoffmann-La Roche542 enrolled76 locationsNCT04929223
Recruiting
Phase 1Phase 2
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
Advanced Solid Tumors CancerMSI-H Cancer
Nimbus Wadjet, Inc.134 enrolled22 locationsNCT06898450
Recruiting
Phase 1Phase 2
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Non-small Cell Lung Cancer
Hoffmann-La Roche320 enrolled71 locationsNCT05789082
Recruiting
Phase 1Phase 2
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Advanced Solid TumorMetastatic Solid Tumor
Daiichi Sankyo540 enrolled33 locationsNCT05875168
Recruiting
Phase 1
A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab, and Inavolisib Plus Pembrolizumab in PIK3CA-Mutated Cancers
PIK3CA-Mutated Cancers
Hoffmann-La Roche30 enrolled8 locationsNCT06496568
Recruiting
Phase 3
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Cancer
Hoffmann-La Roche100 enrolled57 locationsNCT05862285
Recruiting
Phase 2
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
Adenocarcinoma, Pancreatic Ductal
Genentech, Inc.260 enrolled89 locationsNCT05968326
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
Muscle-invasive Urothelial Carcinoma
Hoffmann-La Roche362 enrolled107 locationsNCT06534983
Recruiting
Phase 3
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche1,050 enrolled351 locationsNCT06065748
Recruiting
Phase 1Phase 2
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Hoffmann-La Roche940 enrolled38 locationsNCT03075696
Recruiting
Phase 3
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Low Grade Serous Ovarian Cancer
Verastem, Inc.270 enrolled106 locationsNCT06072781
Recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
Colorectal, CancerAdvanced Solid Tumors
Vividion Therapeutics, Inc.280 enrolled29 locationsNCT06004245